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BACKGROUND: Peripheral blood CD8
 T cells expres-
sing interferon gamma and interleukin-4 (IL-4), and
lacking CD28 molecules, were responsible for the
dynamic interplay between peripheral blood and
inflammatory sites.
Introduction: The aim of the current study was to
define in Behc ¸et’s disease (BD), CD8
 T-cell subsets
using CD28 and CD11b monoclonal antibodies, and
the characterization of the Tc1/Tc2 ratio and perforin
expression.
Methods: Flow cytometry was used for intracytoplas-
mic cytokines and perforin expression. Effector
cells were investigated by adhesion of CD8
 T cells
to human microvascular endothelial cells and by
chemotaxis using b-chemokine.
Results: Interferon-gamma-producing CD8
 T cells
in active and remission BD patients were increased,
which induce a significant increase of the Tc1:Tc2
ratio in BD. CD8
CD28
CD11b
 T cells were found
to be more expanded in BD patients than in age-
matched healthy controls. The expression of CD11b
molecules in active BD allowed to CD8
CD28
/
CD8
CD28
 subsets to adhere to human microvas-
cular endothelial cells, with more efficiency in BD.
Using MIP-1a, we observed that the migratory process
of CD28
CD11b
 is more important in BD.
CD28
CD11b
 exhibited an increased perforin
expression in BD patients.
Conclusion: Taken together these results suggest the
presence of immune activation, probably in response
to a profound inflammation affecting BD patients.
The physiopathological significance of these results
were toward autoimmune diseases and/or infectious
process.
Key words: Behc ¸et’s disease, CD8 T cells, Inﬂammation,
MIP-1a, Human microvascular endothelial cells
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Introduction
Behc ¸et’s disease (BD) is an inflammatory multi-
systemic disorder with mucocutaneous, ocular,
arthritic, vascular and central nervous system invol-
vement.
1 BD is characterized by spontaneous remis-
sions and relapses similar to those of various
autoimmune diseases. Neutrophil hyperactivity with
increased superoxide production, phagocytosis,
release of enzymes and the implication of Heat-shock
proteins in BD suggest an activated innate immunity.
2
Investigation of the aetiology of BD has focused
predominantly on herpes simplex virus immuno-
pathology, streptococcal infection, and autoimmunity
to oral or cross-reactive microbial antigens.
3,4 Only
CD4
  cells and Th1/Th2-type immune responses
were currently investigated in cell-mediated immu-
nity and inflammation in BD;
5 7 CD8
  T-cell subsets
and Tc1/Tc2 cytokine expression were scarcely
reported.
In a number of situations ranging from chronic
inflammatory conditions, infectious
8,9 to autoimmune
diseases,
10 a dysregulation in CD8
  T cells by lacking
CD28 molecule (costimulatory molecule) and expres-
sion of CD11b marker (b2 integrin a-chain) was
reported. CD8
 CD28
  T cells are characterized by
morphological and functional features of activated/
memory T cells.
11 CD11b marker expression can
distinguish between memory-type and effector-type
T cells in human CD8
 CD28
  T subsets.
12 Perforin,
a pore-forming protein stored intracellulary that is
produced by natural killer cells, gamma/delta (g/d)
cells and CD8
  T lymphocytes has been reported in
elevated concentrations in several chronic inflamma-
tory disorders.
13 Perforin can induce apoptosis in a
number of cells and thus might also play a role in the
resolution of inflammatory responses by eliminating
inflammatory or virally infected cells.
14,15
The aim of the current study was to define the
Tc1/Tc2 ratio, the pattern of expression of CD28,
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247CD11b monoclonal antibodies on CD8
  T cells, and
the function of CD8
  naı ¨ve/memory effector cells in
peripheral blood from BD.
Materials and methods
Patients and control subjects
Patients with BD (five females and 31 males) were
studied during the clinically active stage. The mean
age of active BD was 32 years (range, 27 /52 years)
and the mean duration of disease was 74 months
(range, 10 /168 months). All active BD patients
were showing at least three of the four major
symptoms, including recurrent aphthous stomatitis,
uveitis, genital ulcers, and skin lesions (erythema
nodosum, folliculitis or subcutaneous thrombo-
phlebitis). Peripheral blood was obtained from BD
in the active stage before treatment, and clinical
activity was assessed at the time of venipuncture for
activity signs and symptoms (clinical criteria defined
by the International Study Group).
16 Nine BD
patients have pulmonary manifestations (chronic
cough, pulmonary aneurysms) and 12 other BD
patients were diagnosed as having progressive
neuro-Behc ¸et’s (persistent and progressive central
nervous system manifestations for at least 1 year).
After venipuncture, active BD patients received
treatments, including steroids and colchicine. Remis-
sion BD group was composed of asymptomatic
patients (mean duration of remission, 2 months).
Their mean age was 39 years (range, 36 /50 years).
No patient was studied in both stages. Twenty
healthy volunteers, composed of laboratory person-
nel (mean age, 42 years; range, 22 /50 years),
participated after giving informed consent. At the
time of venipuncture, none of the blood donors had
been receiving any medication or had an overt
infection. The design of the study was approved by
our National Ethics Committee.
Cell preparation
Mononuclear cells were separated from heparinized
venous blood that was mixed with 20 ml of Hanks’s
balanced salt solution (Gibco, Grand Island, NY,
USA), using Ficoll-Paque (Pharmacia, Uppsala,
Sweden) density gradient centrifugation. The cells
were washed twice in phosphate-buffered saline
(PBS), and then resuspended in PBS supplemented
with 5% foetal calf serum. The former cell suspen-
sions were finally adjusted to a concentration of
2  /10
6 cells/ml, and were processed further for
intracellular staining studies.
Flow cytometric analysis
Lymphocyte subsets were evaluated on whole fresh
blood using different monoclonal antibodies (mAbs)
panels. Two-colour and three-colour phenotypic
characterizations of lymphocytes were performed as
previously described.
12 Briefly, 100 ml of heparinized
blood was incubated for 30 min on ice with the
appropriate amounts of mAb. Cells were then lysed
with buffer (FACS lysing solution; Becton Dickinson,
Stockholm, Sweden) and analysed by flow cytometry
(FACScan; Becton Dickinson). The lymphocyte gate
was set using the log fluorescence of a two-colour
mAb panel (Leukogate (anti-CD28 and anti-CD11
mAbs); Becton Dickinson) with linear 908 side scatter.
The resulting data were analysed with CellQuest
software (Becton Dickinson).
Purification of CD8
  T-cell subsets
CD8
  cells were purified from lymphocytes by
positive selection using anti-CD8 magnetic beads
(Miltenyi Biotec, Sunnyvale, CA, USA) as we have
recently reported.
6 Sorting of CD8
 CD28
 CD11b
 ,
CD8
 CD28
 CD11b
 , and CD8
 CD28
 CD11b
  T
cells was performed from purified CD8
  lympho-
cytes stained with FITC-conjugated anti-CD11b
(Immunotech, Marseille, France), PE-conjugated
anti-CD28, and PerCP-conjugated anti-CD3, by flow
cytometry (EPICS XL; Coulter Electronics, Hialeah,
FL, USA). Only preparations with purity   /98% were
used for experiments.
Flow cytometric analysis of interferon gamma
and interleukin-4 intracellular cytokine synthesis
Intracellular cytokine detection was performed as
previously described.
6 Purified CD8
  T cells were
incubated in a medium containing phorbol myristate
acetate (50 ng/ml), ionomycin (100 ng/ml) and
monencin (20 mM) (Sigma Chemical Co., St Louis,
MO, USA) for 6 h. Then CD8
  T cells were collected
and intracellular staining of interferon gamma (IFN-g)
and interleukin (IL)-4 was performed by flow cyto-
metry as previously described.
6 Briefly, CD8
  T cells
were washed with PBS, supplemented with 0.5%
bovine serum albumin (BSA) (GIBCO, Grand Island,
NY, USA). After washing, cells were fixed with 4%
formaldehyde for 15 min at room temperature,
washed twice with PBS containing 0.5% BSA and
then permeabilized with PBS containing 0.5% BSA
and 0.5% saponin. Cells were incubated with PE-
conjugated anti-IL-4 or with FlTC-conjugated anti-
IFN-g MoAb. Cells were then washed with PBS
containing 0.5% BSA and 0.5% saponin and next
washed with PBS. Finally, cells were stained with
biotin-labelled anti-CD8 MoAb, followed by RED670-
conjugated streptavidin. After washing with PBS, the
H. Houman et al.
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and the percentage of cells expressing the cytokine
were recorded.
Lymphocyte adhesion to human microvascular
endothelial cell cultures
Primary cultures of human adrenal gland capillary
endothelial cells (HACECs) were obtained as pre-
viously described.
12 The endothelial cells were plated
onto collagenated 96-well plates at a concentration of
5  /10
3/well in 100 ml of endothelial basal medium
(EBM) containing 10% fœtal calf serum, heparin (100
mg/ml), epidermal growth factor (10 ng/ml), and
bovine brain extract (15 mg/ml; EBM complete
medium). The plates were incubated for 4 /5 days
to obtain a monolayer. Endothelial cells were acti-
vated by adding tumour necrosis factor alpha (10 ng/
ml) for 6 h at 378C. Cells were then washed with PBS
and allowed to interact with purified CD8
  T-cell
subsets (2  /10
4 lymphocytes/well in RPMI 1640,
containing 0.2% BSA). The plates were incubated
for 2 h at 378C, and unbound lymphocytes were
removed by three washes with warm PBS. The
lymphocytes attached to endothelial cells were fixed
for 5 min with 100 ml of cold methanol, and the cells
were stained with Diff-Quick (Merz-Dade, Dudingen,
Switzerland) for 30 min at room temperature. Plates
were then washed several times with deionized
water, and the lymphocytes bound to endothelial
cells were counted with a calibrated eyepiece in 15
different fields at   /200 magnification. Each test was
run in quadruplicate.
Chemotaxis and migration assays
All migration assays were performed in collagen-
coated 24-well Trans-well culture inserts (6.5 mm
diameter clear polycarbonate membrane with 3-mm
pores; Costar, Cambridge, MA, USA). The medium
used was RPMI 1640 containing 0.2% BSA. All
migration assays were conducted for 4 h at 378C.
Purified CD8
  T-cell subsets (2  /10
5) were placed in
the upper chamber in 200 ml, and then 500 mlo f
medium containing, or not, MIP-1a was added in the
lower well. The optimal chemotactic dose for MIP-1a
was 100 ng/ml.
Intracellular perforin staining
After incubation of CD8 T cells with anti-CD28, and
anti-CD11b, cells were fixed in paraformaldhehyde
(4% in PBS) for 15 min on ice, washed twice and
permeabilized with saponin (0.1% in PBS). Subse-
quently, cells were incubated with FITC-conjugated
anti-perforin antibodies for 30 min, washed twice
again, and then analysed by flow cytometry.
Statistical analysis
Mann /Whitney U-tests were used to compare vari-
ables between two groups. Bonferroni’s test was used
for multiple comparisons. pB /0.05 was considered
statistically significant.
Results
Intracellular cytokine analysis in CD8
  T cells
Cytokine-producing CD8
  T cells were assessed in
BD patients, compared with healthy controls, after
stimulation for 12 h with phorbol myristate acetate
and ionomycin at the single cell level, using intracel-
lular cytokine staining and flow cytometry with two-
colour analysis (Fig. 1). Samples obtained from
unstimulated culture were negative for any of these
FIG. 1. Frequencies of CD8
  T cells producing IFN-g and IL-4 in peripheral blood from BD in active and remission stage and
from normal controls (HC). Intracellular expression of IL-4 and IFN-g were determined by ﬂow cytometry. Bars indicate the
medians. Open squares, with central nervous system and pulmonary manifestations. (A) IFN-g-producing cells. (B) IL-4-
producing cells. NS, not signiﬁcant.
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  T cells in active
and remission BD patients were respectively more
increased (median, 60%; range, 40 /79%; median,
52.5%; range, 40 /70%) than normal controls
(median, 37%; range, 16 /54%; pB /0.001) (Fig. 1A).
When BD patients were studied according to their
clinical manifestations, the frequencies of IFN-g-
producing CD8
  T cells were significantly higher in
patients with pulmonary manifestations (median,
73%; range, 70 /79%; pB /0.001), and in patients
with central nervous system manifestations (median,
76%; range, 68 /82%), when compared with BD
patients without these manifestations (median, 57%;
range, 40 /63%; p B /0.05).
No significant difference was found in the propor-
tion of IL4-producing cells among CD8
  T cells
between BD groups and normal controls (Fig. 1B).
The Tc1:Tc2 ratio was evaluated from IFN-g to IL-4-
producing cells. The Tc1:Tc2 ratios of CD8
  T cells in
active (median, 14.5; range, 25.3 /8) and remission
BD patients (median, 12.9; range, 23.3 /9.8; pB /0.05)
exhibited a drastic increase, when compared with
control subjects (median, 8; range, 11.6 /4). The
Tc1:Tc2 were similar in BD patients in active and
remission phases.
CD28 and CD11b expression on CD8
  T
lymphocytes in BD
Three subsets of CD8
  T lymphocytes (CD28
 
CD11b
 , CD28
 CD11b
  and CD28
 CD11b
 )
were revealed as presented in Table 1. In healthy
controls, the CD11b
  prevailed over CD11b
  sub-
sets. The CD28
 CD11b
  subset was barely present
in healthy controls (median, 7.4; range, 5 /8), when
compared with active and remission BD (p B /0.05). In
patients suffering from active and remission BD, we
observed a significant increase in CD28
 CD11b
 
cells (pB /0.01), when compared with the same
subset in healthy controls. CD28
 CD11b subset
was highly expressed in healthy controls compared
with active and remission BD patients (p B /0.01).
Adhesion of CD8
  T-cell subsets to HACECs,
chemotaxis
We investigated the adhesion of CD28
 CD11b
  and
CD28
 CD11b
  subsets to HACECs, both in healthy
controls and in active BD. In active BD,
CD28
 CD11b
  cells adhere to HACECs at higher
levels than the same subset in healthy controls
(pB /0.05) (Fig. 2A). Both in BD patients and in
healthy controls, the expression of CD11b molecules
allowed CD8
 CD28
 /CD8
 CD28
  subsets to
adhere to HACECs; the efficiency of the adhesion
Table 1. CD28 and CD11b expression on CD8
  T lympho-
cytes from BD, compared with healthy controls
Healthy
controls
Active BD Remission BD
CD28
 CD11b
  72 (59 /78) 37.2 (32 /40)
$ 39 (22 /47)
$
CD28
 CD11b
  7.4 (5 /8) 22 (15 /35)* 20.5 (29 /46)*
CD28
 CD11b
  19 (12 /24) 36 (27 /44)
$ 38 (25 /34)
$
Staining with monoclonal antibodies to CD8, CD11b and CD28 with
three-colour analysis. * Significant differences (pB /0.05) compared
with the same subset of healthy controls.
$ Significant differences
(pB /0.01) compared with the same subset of healthy controls.
FIG. 2. Function of CD8
 CD28
 / CD11b
 /  T-cell subsets.
(A) Binding to HACECs. Cells allowed to interact with a
monolayer of tumour necrosis factor alpha-stimulated HA-
CECs. Lymphocytes bound to HACECs were counted using a
calibrated eyepiece in 10 different ﬁelds at (  /200) magniﬁ-
cation. (B) Migration in active BD. The number of cells
migrating into the bottom well in the absence or presence
of MIP-a was evaluated by counting cells from duplicate
wells. The net migration of cells was calculated by subtract-
ing the number of cells migrating in the absence of a
chemoattractant from the number of cells migrating in
response to MIP-1a. Each test was run in quadruplicate.
Bars represent the mean number of CD8
 CD28
 CD11b
 ,
CD8
 CD28
 CD11b
 , CD8
 CD28
 CD11b
  T cells per
microscopic ﬁeld9 /standard deviation. The experiments are
representative of results obtained with cells from four
healthy controls and seven active BD patients.
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  cells that have lacked
CD28 antigen, particularly in active BD.
Using MIP-1a, we observed that both
CD28
 CD11b
  and CD28
 CD11b
  from healthy
controls and BD patients were efficiently attracted by
the chemokine, whereas CD28
 CD11b
  cells were
unable to respond to chemotactic stimulus (Fig. 2B).
MIP-1a is a b-chemokine that regulates T-lymphocyte
migration from vessels to tissues. The migratory
process of CD28
 CD11b
  T cells is more impor-
tant in active BD compared with healthy controls
(pB /0.001).
Perforin expression in CD8
  subsets
We investigated intracellular perforin expression in
the three CD8
  subsets. Freshly isolated CD8
  cells
were stained with anti-CD28, anti-CD11b, and anti-
perforin mAbs, and were analysed by flow cytometry.
CD28
 CD11b
  did not contain perforin both in
healthy controls and patients with BD (median, 4%;
range, 0 /6%), while high staining was observed in
the CD28
  population. CD28
 CD11b
  exhibited an
increased perforin expression in BD patients (med-
ian, 57%; range, 33 /62%) compared with healthy
subjects (median, 22%; range, 12 /34%) (pB /0.01). In
patients with BD and in healthy controls,
CD28
 CD11b
  cells expressed similar levels of
perforin (BD: median, 23%; range, 11.5 /27%; healthy
controls: median, 25%; range, 9 /24%).
Discussion
In this study, intracellular cytokine analysis at the
single cell level showed that the numbers of IFN-g-
producing CD8 T cells in active BD were increased
compared with normal controls. In patients with BD,
and in healthy controls, CD8
  cells were exclusively
producer of IFN-g, they express insignificant IL-4
cytokine level. The main source of IL-4 were CD4
 
cells, as reported by Matsui et al.
17 Evidence sug-
gested that BD was characterized by an increased
Tc1/Tc2 ratio, in the same way as it has been reported
in Th1/Th2 ratio.
5,6 Th1(IFN-g) cells are involved in
the protection against intracellular parasites and
delayed-type hypersensitivity, but they can cause
autoimmune diseases.
18 We have also demonstrated
the occurrence of an unreported CD8
 CD28
  T-cell
subset in BD. The increase in such cells was not
transient, as their percentage was highly expressed
both in active and remission stages. The finding
suggests the hypothesis that the presence of such
cells during BD plays an important role in defence
against a hypothetic aetiological agent.
2 4 Recently, it
has been reported that neuro-BD has a cytokine
and chemokine pattern in resemblance with non-
specific inflammations such as neuro-infections com-
pared with autoimmune disorders.
19 Circulating
CD8
 CD28
  T cells are increased not only in various
infectious diseases,
20 but also in patients with auto-
immune diseases.
10 In rheumatoid arthritis patients,
cytomegalovirus seropositivity has been directly
correlated with increased levels of CD8
 CD28
  T
cells.
21 Weeks et al.
22 reported that functional virus-
specific memory CTL clones are present in
CD8
 CD28
  T cells expressing or no CD57 marker
(HNK-1). CD8
 CD28
  T cells have been reported to
be effector cells, producing perforin, granzyme B,
tumour necrosis factor alpha and IFN-g.
23,24
Although this is the first study to report an incr-
ease in the percentage of perforin-expressing
CD8
 CD28
  in patients with BD, our study cannot
provide conclusive evidence of perforin-cytotoxicity
in BD. Their relative cytotoxic potential must remain
unclear since to date there are no studies that have
satisfactorily addressed this question in BD. However,
we have previously reported that patients with BD
have elevated cytolytic CD8
  T lymphocytes
in peripheral blood against HSV1 target cells.
25
Increased perforin expression has been reported in
several other chronic inflammatory disorders with
autoimmune phenomena such as multiple sclerosis,
26
Takaysu’s arthritis
27 and Crohn’s disease.
28 In an
animal model of lupus erythematosus, perforin-
deficient animals had more severe disease, suggest-
ing that cytolytic lymphoid regulation plays a critical
role in the immune homeostasis of these animals.
29
One of the effects of IFN-g is to suppress the
development of Th2 cytokines
18,30 and point to the
effector potential of CD8
  T cells.
31 IL-4 prompts
CD8
  T cells to maintain CD28 expression in long-
term cultures.
32 The addition of IL-4 led both the
neonatal and the adult lymphocytes to keep their
expression of CD28.
32,33 Besides, delayed addition of
IL-4 to CD8
  T cell cultures did not re-induce CD28
on cells that have already lost the marker, indicating
that IL-4 can prevent, but cannot reverse, the switch
in CD28 expression
Our BD data demonstrate that CD8
  T-cell differ-
entiation into effector cells is characterized by acquisi-
tionofaCD11b
 phenotype.Indeed,CD28
 CD11b
 
cells are more similar in behaviour to true memory
cells, being incapable of chemotaxis and adhesion
to human microvascular endothelial cells, whereas
their CD11b
  counterpart has all the properties of
fully competent effector cells. As suggested, the
CD28
 CD11b
  subset provides a model for a critical
step in the development of functional CTL, which
precedes the process of CD28 downregulation.
12 In
functional terms, CD8
 CD28
  cells share features of
both CD28
  and CD28
  T cells. CD8
 CD28
  cells
are relatively resistant to apoptosis compared with
their CD8
 CD28
  precursors.
34 CD8
 CD28
  have
shorter telomers than CD8
 CD28
  cells, indicating a
Phenotype and function of CD8
  cells in Behc ¸et’s disease
Mediators of Inflammation Vol 13  2004 251history of increased cell divisions.
35,36 The persistence
of the expanded in vivo CD8
 CD28
  subset may be
explained by antigen-driven differentiation from
CD8
 CD28
  memory precursors, with relative resis-
tance to apoptosis as the clones become perforin-
positive effector cells. We have reported that patients
with BD expressed high levels of soluble Fas/APO-1,
which may be a useful marker in evaluating the extent
of injury in vasculitis conditions.
37 Patients with
active BD expressed high levels of the bcl-2 in
inflammatory sites,
38 and the chronic inflammation in
BD was confirmed by the increased amount of bcl-2
messenger RNA.
39
Cells migrating to lymph nodes lack inflammatory
and cytotoxic function, whereas cells migrating to
peripheral tissues are endowed with various effector
functions.
40 CD11b
  cells are present in blood;
41
they have been described as an important molecule
for the extravasation of neutrophils and monocytes to
the site of inflammation */ it is also involved in
adhesion, chemotaxis, and diapedesis.
42 Our report
demonstrates an increase in the capacity of CD28
 
cells to migrate in response to MIP-1a at the time
that they acquire expression of CD11b, thus
supporting the prospect of an effector CD28
 /
CD28
  subset with tissue-homing properties. Our
BD patients, having pulmonary or central nervous
system manifestations were characterized by ex-
panded CD8
 CD28
 CD11b
  cells, which govern
transition to the inflammatory sites. Such investiga-
tions allow us to manipulate cells for immunoth-
erapy purposes. In our patients, the level of
CD8
 CD28
 CD11b
  was scarcely represented.
The biologic properties of CD8
 CD28
 CD11b
  T
cells suggest that these cells might be end stage or
aberrant differentiated effector cells. It has been
reported that if CD8
 CD28
 CD11b
  T cells lacked
cell /cell adhesion and impaired cytolytic functions,
this would favour the hypothesis of a role for the
development of immunodeficiency.
43 Several obser-
vations suggest that the phenotypic evolutions de-
tected in long-term cultures from healthy adult donors
also occur in vivo: (i) CD8
  T cells with high,
moderate and low CD28 density can be identified in
normal adult blood;
33 (ii) progressive emergence of
CD8
 CD28
  T cells has been observed in healthy
human adults, particularly but not exclusively in
elderly subjects, and considerably more during
many clinical situations associated with inflammation,
chronic immune responses,
44 46 where some patho-
gens, such as herpes simplex virus,
47 cytomegalovirus
and Epstein /Barr virus,
34,48 are never eliminated, and
maintenance of a high frequency of virus-specific
CD8
  T cells is essential to prevent viral reactivation
from becoming symptomatic.
Our report suggests that the BD immune system
reflects an autoimmune and/or viral situation, and
CD8
  T cells acquire or lose markers according to
the extended inflammatory process. We have shown
a strong shift to Tc1 cells among CD8
  T cells in
peripheral blood from BD patients, the persistence of
the expanded in vivo CD8
 CD28
  subset, which
may be explained by antigen-driven differentiation
from CD8
 CD28
  memory precursors, with relative
resistance to apoptosis as these cells become per-
forin-positive effector cells. In general, it would
be important for CD8 effector cells to avoid apopto-
sis. It undergoes repetitive antigen exposure when it
serially kills one target after another.
49 Perhaps this
is the reason of the loss of CD28 and acquisition of
CD11b expression in perforin-positive cells. Expan-
sion of CD28
  T cells are not a distinctive feature
of some special antigenic stimulation, but instead
would merely reflect repeated stimulations of the BD
immune system by any persisting antigen.
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